Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Sandoz Group AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1986-01-01

Employees: 20K

Market Cap: $19B

Website: http://www.sandoz.com

Clinical Trials

MONITOR-CKD5 - Multi-level Evaluation of Anaemia Treatment, Outcomes, and Determinants in Chronic Kidney Disease Stage 5

Completed

Conditions: Chronic Kidney Disease
End-stage Renal Disease
Anaemia

Interventions: Drug: Recombinant human erythropoietin alfa (biosimilar)

First Posted Date: 2010-05-12

Last Posted Date: 2016-04-06

Lead Sponsor: Sandoz

Target Recruit Count: 2086

Registration Number: NCT01121237

Locations: 🇬🇧
Sandoz Investigational Site, Plymouth, United Kingdom

A Study Comparing the Clinical Equivalence of Two Mometasone Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

Phase 3

Completed

Conditions: Rhinitis, Allergic, Seasonal

Interventions: Drug: Mometasone furoate 50 mcg/actuation nasal spray (Lek Pharmaceuticals)
Drug: Mometasone furoate (Nasonex®) 50 mcg/actuation nasal spray
Drug: Placebo

First Posted Date: 2009-12-24

Last Posted Date: 2021-02-03

Lead Sponsor: Sandoz

Target Recruit Count: 795

Registration Number: NCT01038427

Locations: 🇺🇸
Sylvana Research, San Antonio, Texas, United States

Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions

Phase 1

Completed

Conditions: High Blood Pressure
Migraine Headaches
Chest Pain

Interventions: Drug: Nadolol (1 x 80 mg) Tablets (Invamed, Inc)
Drug: Corgard (1 x 80 mg) Tablets (Bristol Laboratories)

First Posted Date: 2009-08-17

Last Posted Date: 2017-03-28

Lead Sponsor: Sandoz

Target Recruit Count: 34

Registration Number: NCT00960245

Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Non-Fasting Conditions

Phase 1

Completed

Conditions: Chronic Hepatitis C

Interventions: Drug: Rebetol 200 Capsules (Schering Corporation, U.S.A.)
Drug: Ribavirin 200 Capsules (Geneva Pharmaceutical, U.S.A.)

First Posted Date: 2009-08-17

Last Posted Date: 2017-03-28

Lead Sponsor: Sandoz

Target Recruit Count: 24

Registration Number: NCT00959933

Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fed Conditions

Phase 1

Completed

Conditions: Hirsutism
Prostate Cancer

Interventions: Drug: Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)
Drug: Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)

First Posted Date: 2009-08-17

Last Posted Date: 2017-03-28

Lead Sponsor: Sandoz

Target Recruit Count: 36

Registration Number: NCT00960310

Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Fasting Conditions

Phase 1

Completed

Conditions: Chronic Hepatitis C

Interventions: Drug: Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.)
Drug: Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)

First Posted Date: 2009-08-17

Last Posted Date: 2017-03-28

Lead Sponsor: Sandoz

Target Recruit Count: 38

Registration Number: NCT00960479

Relative Bioavailability Study of Naproxen Delayed-Release Tablets (375 mg)

Phase 1

Completed

Conditions: Rheumatoid Arthritis
Osteoarthritis

Interventions: Drug: Naproxen Delayed Release Tables, 375 (Gevena Pharmaceuticals, Inc.)
Drug: Naproxen (EC-Narosyn) Delayed Release Tables, 375 (Syntex (USA), Inc.)

First Posted Date: 2009-08-14

Last Posted Date: 2017-03-28

Lead Sponsor: Sandoz

Target Recruit Count: 34

Registration Number: NCT00959439

Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fasting Conditions

Phase 1

Completed

Conditions: Hirsutism
Prostate Cancer

Interventions: Drug: Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)
Drug: Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)

First Posted Date: 2009-08-14

Last Posted Date: 2017-03-28

Lead Sponsor: Sandoz

Target Recruit Count: 36

Registration Number: NCT00959335

To Demonstrate the Relative Bioavailability Study of Loratadine 10 mg Tablets

Phase 1

Completed

Conditions: Allergy

Interventions: Drug: Loratadine 10 mg Tablets Under Fasting Conditions (Sandoz, Inc.)
Drug: Loratadine 10 mg Tablets Under Fed Conditions (Sandoz, Inc.)
Drug: Claritin (Loratadine) 10 mg Tablets Under Fed Conditions (Schering)

First Posted Date: 2009-07-27

Last Posted Date: 2017-03-28

Lead Sponsor: Sandoz

Target Recruit Count: 30

Registration Number: NCT00946608

To Demonstrate the Relative Bioavailability Study of Promethazine HCl 50 mg Tablets Under Fasting Conditions

Phase 1

Completed

Conditions: Allergy

Interventions: Drug: Phenergan (Promethazine HCl) 50 mg Tablets (Wyeth Laboratories)
Drug: Promethazine HCl 50 mg Tablets (Sandoz, Inc)

First Posted Date: 2009-07-27

Last Posted Date: 2017-03-28

Lead Sponsor: Sandoz

Target Recruit Count: 36

Registration Number: NCT00947063

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy